Median: criteria met for eyonis LCS software

(CercleFinance.com) - Median Technologies announces that its eyonis LCS medical software, using AI and machine learning for lung cancer screening, has met all the criteria of the REALITY study, the first of two studies required to obtain marketing approvals in the USA and Europe.


Designed to improve the detection and accuracy of low-dose CT (LDCT) scans, eyonis LCS could significantly improve early detection of lung cancer and reduce associated mortality.

Median expects to submit regulatory applications in the first half of 2025.

Copyright (c) 2024 CercleFinance.com. All rights reserved.